WO2007137224A3 - Method of treatment - Google Patents

Method of treatment Download PDF

Info

Publication number
WO2007137224A3
WO2007137224A3 PCT/US2007/069366 US2007069366W WO2007137224A3 WO 2007137224 A3 WO2007137224 A3 WO 2007137224A3 US 2007069366 W US2007069366 W US 2007069366W WO 2007137224 A3 WO2007137224 A3 WO 2007137224A3
Authority
WO
WIPO (PCT)
Prior art keywords
patients
treatment
psychotic
depression
features
Prior art date
Application number
PCT/US2007/069366
Other languages
French (fr)
Other versions
WO2007137224A2 (en
Inventor
Mihael H Polymeropoulos
Curt D Wolfgang
Gunther Birznieks
Deepak Phadke
Original Assignee
Vanda Pharmaceuticals Inc
Mihael H Polymeropoulos
Curt D Wolfgang
Gunther Birznieks
Deepak Phadke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc, Mihael H Polymeropoulos, Curt D Wolfgang, Gunther Birznieks, Deepak Phadke filed Critical Vanda Pharmaceuticals Inc
Publication of WO2007137224A2 publication Critical patent/WO2007137224A2/en
Publication of WO2007137224A3 publication Critical patent/WO2007137224A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Combinations and combination therapies for the treatment of insomnia in patients with psychotic disorders or with psychotic features, patients with bipolar depression, and patients with major depression with psychotic features.
PCT/US2007/069366 2006-05-22 2007-05-21 Method of treatment WO2007137224A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74786606P 2006-05-22 2006-05-22
US60/747,866 2006-05-22

Publications (2)

Publication Number Publication Date
WO2007137224A2 WO2007137224A2 (en) 2007-11-29
WO2007137224A3 true WO2007137224A3 (en) 2008-01-24

Family

ID=38724065

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/069366 WO2007137224A2 (en) 2006-05-22 2007-05-21 Method of treatment

Country Status (1)

Country Link
WO (1) WO2007137224A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012015084A2 (en) * 2009-12-23 2017-03-07 Lupin Ltd iloperidone slow release pharmaceutical composition
FR2978916B1 (en) * 2011-08-10 2013-07-26 Servier Lab SOLID PHARMACEUTICAL COMPOSITION FOR BUCCAL ADMINISTRATION OF AGOMELATIN
EP3558275A1 (en) 2016-12-20 2019-10-30 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine
CA3047354A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
EP3644973B1 (en) 2017-06-26 2021-03-24 LTS LOHMANN Therapie-Systeme AG Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
CN112236138B (en) 2017-12-05 2024-05-31 赛诺维信制药公司 Crystal forms and methods of making the same
AU2018379992B2 (en) 2017-12-05 2022-07-21 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
CN112704672A (en) 2018-06-20 2021-04-27 罗曼治疗系统股份公司 Transdermal therapeutic system comprising asenapine
CN114401717A (en) 2019-06-04 2022-04-26 赛诺维信制药公司 Modified release formulations and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5276051A (en) * 1991-08-13 1994-01-04 Adir Et Compagnie Arylethylamine compounds
US6352984B1 (en) * 1998-11-23 2002-03-05 Sepracor Inc. Olanzapine-N-oxide compositions and methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5276051A (en) * 1991-08-13 1994-01-04 Adir Et Compagnie Arylethylamine compounds
US6352984B1 (en) * 1998-11-23 2002-03-05 Sepracor Inc. Olanzapine-N-oxide compositions and methods

Also Published As

Publication number Publication date
WO2007137224A2 (en) 2007-11-29

Similar Documents

Publication Publication Date Title
WO2007137224A3 (en) Method of treatment
PH12017500930A1 (en) Hsp90 inhibitor combinations
IL190796A0 (en) Compositions and their uses for gene therapy of bone conditions
WO2008036144A3 (en) Nanoshells on polymers
WO2007146426A3 (en) Nanoshells for drug delivery
ZA201201391B (en) Methods, compositions, and kits for the treatment of medical conditions
WO2009043051A3 (en) Cd23 binding molecules and methods of use thereof
WO2007146411A3 (en) Nanoshell therapy
WO2008067389A3 (en) Modulation of sod protein synthesis for the treatment of neurodegenerative diseases
WO2008003007A3 (en) Compositions and methods for treating parasitic infections
WO2010033587A3 (en) Methods for treating progressive multiple sclerosis
WO2009009587A3 (en) Apoptosis-modulating protein therapy for proliferative disorders and nanoparticles containing the same
IL182222A0 (en) Treatment of bipolar disorders and associated symptoms
WO2009085271A3 (en) Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of orthopedic conditions
WO2005108428A3 (en) Cd40 splice variants and their uses
WO2008029169A3 (en) Method of treating respiratory disorders
UA88655C2 (en) S-mirtazapine for the treatment of hot flush
WO2007028151A3 (en) Surgical devices and related methods thereof
TW200509896A (en) Analeptic and drug combinations
IL200570A0 (en) Combination therapy, composition and methods for the treatment of cardiovascular disorders
WO2009098464A3 (en) Use of g-rich oligonucleotides for treating neoplastic diseases
WO2007101106A3 (en) Compositions and methods for modulating hemostasis using variant forms of activated factor v
WO2010033392A3 (en) Methods and kits for treating cluster headache disorders
WO2008042898A3 (en) Ketoconazole enantiomer in humans
WO2008085927A3 (en) Methods, compositions, and kits for the treatment of pain

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07762272

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07762272

Country of ref document: EP

Kind code of ref document: A2